Skip to main content
PMC home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2002;10(2):71–77. doi: 10.1155/S1064744902000054

Acyclovir suppression to prevent recurrent genital herpes at delivery.

L L Scott 1, L M Hollier 1, D McIntire 1, P J Sanchez 1, G L Jackson 1, G D Wendel Jr 1
PMCID: PMC1784606  PMID: 12530483

Abstract

OBJECTIVE: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. METHODS: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. RESULTS: Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102). CONCLUSIONS: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.

Full Text

The Full Text of this article is available as a PDF (114.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvin A. M., Hensleigh P. A., Prober C. G., Au D. S., Yasukawa L. L., Wittek A. E., Palumbo P. E., Paryani S. G., Yeager A. S. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med. 1986 Sep 25;315(13):796–800. doi: 10.1056/NEJM198609253151303. [DOI] [PubMed] [Google Scholar]
  2. Benedetti J., Corey L., Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994 Dec 1;121(11):847–854. doi: 10.7326/0003-4819-121-11-199412010-00004. [DOI] [PubMed] [Google Scholar]
  3. Brocklehurst P., Kinghorn G., Carney O., Helsen K., Ross E., Ellis E., Shen R., Cowan F., Mindel A. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol. 1998 Mar;105(3):275–280. doi: 10.1111/j.1471-0528.1998.tb10086.x. [DOI] [PubMed] [Google Scholar]
  4. Brown Z. A., Vontver L. A., Benedetti J., Critchlow C. W., Hickok D. E., Sells C. J., Berry S., Corey L. Genital herpes in pregnancy: risk factors associated with recurrences and asymptomatic viral shedding. Am J Obstet Gynecol. 1985 Sep 1;153(1):24–30. doi: 10.1016/0002-9378(85)90584-8. [DOI] [PubMed] [Google Scholar]
  5. Brown Z. A., Watts D. H. Antiviral therapy in pregnancy. Clin Obstet Gynecol. 1990 Jun;33(2):276–289. doi: 10.1097/00003081-199006000-00010. [DOI] [PubMed] [Google Scholar]
  6. Frenkel L. M., Brown Z. A., Bryson Y. J., Corey L., Unadkat J. D., Hensleigh P. A., Arvin A. M., Prober C. G., Connor J. D. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991 Feb;164(2):569–576. doi: 10.1016/s0002-9378(11)80023-2. [DOI] [PubMed] [Google Scholar]
  7. Hankins G. D., Cunningham F. G., Luby J. P., Butler S. L., Stroud J., Roark M. Asymptomatic genital excretion of herpes simplex virus during early labor. Am J Obstet Gynecol. 1984 Sep 1;150(1):100–101. doi: 10.1016/s0002-9378(84)80119-2. [DOI] [PubMed] [Google Scholar]
  8. Hintz M., Connor J. D., Spector S. A., Blum M. R., Keeney R. E., Yeager A. S. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am J Med. 1982 Jul 20;73(1A):210–214. doi: 10.1016/0002-9343(82)90093-6. [DOI] [PubMed] [Google Scholar]
  9. Löwhagen G. B., Tunbäck P., Andersson K., Bergström T., Johannisson G. First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect. 2000 Jun;76(3):179–182. doi: 10.1136/sti.76.3.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Prober C. G., Corey L., Brown Z. A., Hensleigh P. A., Frenkel L. M., Bryson Y. J., Whitley R. J., Arvin A. M. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis. 1992 Dec;15(6):1031–1038. doi: 10.1093/clind/15.6.1031. [DOI] [PubMed] [Google Scholar]
  11. Prober C. G. Herpetic vaginitis in 1993. Clin Obstet Gynecol. 1993 Mar;36(1):177–187. doi: 10.1097/00003081-199303000-00023. [DOI] [PubMed] [Google Scholar]
  12. Randolph A. G., Hartshorn R. M., Washington A. E. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol. 1996 Oct;88(4 Pt 1):603–610. doi: 10.1016/0029-7844(96)00261-x. [DOI] [PubMed] [Google Scholar]
  13. Randolph A. G., Washington A. E., Prober C. G. Cesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. JAMA. 1993 Jul 7;270(1):77–82. [PubMed] [Google Scholar]
  14. Reiff-Eldridge R., Heffner C. R., Ephross S. A., Tennis P. S., White A. D., Andrews E. B. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):159–163. doi: 10.1016/s0002-9378(00)70506-0. [DOI] [PubMed] [Google Scholar]
  15. Scott L. L., Sanchez P. J., Jackson G. L., Zeray F., Wendel G. D., Jr Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol. 1996 Jan;87(1):69–73. doi: 10.1016/0029-7844(95)00357-6. [DOI] [PubMed] [Google Scholar]
  16. Stray-Pedersen B. Acyclovir in late pregnancy to prevent neonatal herpes simplex. Lancet. 1990 Sep 22;336(8717):756–756. doi: 10.1016/0140-6736(90)92255-g. [DOI] [PubMed] [Google Scholar]
  17. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997 Mar 1;99(5):1092–1097. doi: 10.1172/JCI119237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wald A., Zeh J., Barnum G., Davis L. G., Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8–15. doi: 10.7326/0003-4819-124-1_part_1-199601010-00002. [DOI] [PubMed] [Google Scholar]
  19. Wittek A. E., Yeager A. S., Au D. S., Hensleigh P. A. Asymptomatic shedding of herpes simplex virus from the cervix and lesion site during pregnancy. Correlation of antepartum shedding with shedding at delivery. Am J Dis Child. 1984 May;138(5):439–442. doi: 10.1001/archpedi.1984.02140430017005. [DOI] [PubMed] [Google Scholar]
  20. Yeager A. S. Use of acyclovir in premature and term neonates. Am J Med. 1982 Jul 20;73(1A):205–209. doi: 10.1016/0002-9343(82)90092-4. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES